Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We all get caught up in the day to day action surrounding IPIX. I think it should have been more visible that nothing substantial was going to happen until January. With the new tax laws taking effect there are many benefits to Pharma companies to wait until 2018. It should start to brake loose in January after the accountants determine the most efficient way to structure and pay for new deals. IPIX will be one of them
Funny how everyone has a different idea. I was thinking that a sachet would be like a couple of thin tea bags that you put on the inside of your mouth or that they would have something like listerine strips that would slowly dissolve. Who knows. Maybe you don't mess with success except to say swish thoroughly.
If the tax plan is approved large pharma will have billions of
dollars they can and will most likely repatriate. Will there be a
buying spree of small biotechs in 2018? Candidates?
Leo should announce a 10MM share shelf offering. It should be at the current market price and should include a warrant option, exercisable at a higher price. This would be a minor dilution, would give him money to move forward and would put pressure on any potential partners to fish or cut bait now. I would buy some of these shares, particularly with a warrant.
Bio. Have 2 self directed IRAS. One with fidelity and one with Morgan. Fidelity has been easier to deal with. Trade at will for low cost. Remember IRA is an individual account , not a company account. You may have to do some rearch. Call fidelity, they are very helpful
Would management discuss results with potential partners before revealing them to the public? I know they would love to announce results and then a quick partnership, but should shareholders legally know first?
Did anyone hear the presentation today? Any news
Long Shot: If BOM results are exceptionally significant - is there any chance FDA would approve at that point for outstanding efficacy???
Looking for some feedback. In my estimation KERX is in a once in a decade position. Granted they have turned in mediocre sales performance, but nothing that can't be cured with the proper sales/marketing program. They have the best dialysis drug and new FDA approval for IDA.- a market they have not even begun to tap. Even I couldn't mess this opportunity up. If current management can't make it happen - new management or a new owner will. This is the best investment opportunity I have seen in biotech for some time. This price decrease is a buying opportunity not a selling opportunity. Don't let the shorts win. Your opinion / feedback
KERX . can't find a logic, unless shorts are trading 100share blocks amongst themselves and trying to obtain shares from weak hands to cover their positions. Company has only oral IDA product, best product for dialysis patients and has more than doubled their potential market. I hold some shares and will continue to do so. Company is a potential acquisition if rhey cannot optimize product sales
KERX receives approval
Shorts are trying to get stock out of weak hands so they can cover. Wait for the market to open to get a more clear view.It will go up and down for first few hours. I bought more at 7am
from meeting attendee KERX strong enough for IDA approval. Need strong
KERX PDUFA Today Substantial Positive movement late last Friday.
lets assume RIT results are good, but the FDA again contrives a way to deny approval or ask for further study. Would AMRN make billions marketing themselves as the most effective, study proven supplement on the market? Is this a real possibility and could it be more profitable then going thru the FDA process? Just speculating!
Let's assume RIT results are good, but FDA figures someway to deny approval or ask for further study. Would AMRN make billions marketing themselves as the most effective dietary supplement on the market? Is this a real alternative if the FDA is never going to approve???
Question for the board. Who is benefiting by keeping the stock price low and range bound. News has all been positive. FUD has increased. Price is ridiculously low and someone is offering stock in increments of 1/10000th.
I'm a little baffled
Does anyone have any insight into upcoming KERX PDUFA session in early November?
Been accumulating for 4+ years. small-medium buys each time. Just made my last buy before results. Does anyone have an estimated timeline for each of the trials underway?
Does anyone have a handle on the total amount of shares outstanding including Aspire, options, etc. and the dilutive effect of the most recent announcements.
Everything to date seems to be interim results. Does anyone have a projection on when final results will be complete and communicated. It seems that everything with this company takes longer than expected. I'm very long and hopeful, but getting a lot more gray hair.
Lets not argue. Everyone is a little disappointed and the stock price reflects it. The price will rise going into final review and AMRN management (if successful) will,(like all other small firms) have a secondary offering to raise cash (for a variety of reasons). Let's hope the results are positive and the secondary is not too painful.
Sorry for double tap. Please note that AMRN is a European entity and things are not exactly the same as in the U.S. It should also be noted that most shares tend to go to the top 20% of employees. The receptionist will not have a large stake in this. As part of an ESP it is customary to delay the execution date so as to provide golden handcuffs, keeping key players in their positions while the company is at a critical growth phase. Let's hope AMRN senior management does the same.
I support Employee Stock Purchase plans wholeheartedly (even at a discount). However, Any and all new shares issued will be dilutive to common stock holders like us. Usually companies will put restrictions on such ESP shares such as vesting time frames, maximum # of shares availability for sale per year, etc. As in an IPO sometimes shares are locked up for a period of time. In any case none of these 20MM/23MM shares should be allowed to influence the stock price negatively during the next 12 months. Management can make sure this does not happen.
20MM share offering @ 85% of market price is still a dilution. I don't know the financial impact (cents per share) but I would like to see the company offer the shares to current shareholder before giving it to the shorts so they can cover at a discount.
Can anyone confirm. I thought I saw a filing a few minutes ago (since deleted) that AMRN will be selling 20MM shares at $3.53.
I am as optimistic as anyone for a quantum leap in the stock price over the next 3-12 months. As with all biotechs IPIX will have a secondary offering when very good news hits. I'm not sure what phase/time frame that will be but I am concerned that management will kill the goose before it gets to fly. I'll bet you financial firms are in Leo's ear right now. I think the only way his does not happen is if there is a total sale of the company at the completion of significant phase 2 or 3 results. Any thoughts?
IPIX reports outstanding results. Please see press release
Does the possibility exist that the company receives approval for some label items, but is asked to continue the study for the remaining outcomes. This would give everyone a success and would accomplish the original FDA goal of having the trial run its full course.
Is there anyway to listen in or get feedback on the presentation?
Someone just purchased 1MM share block of AMRN ahead of 2nd interim review. Is there anyway to find out if it was a financial firm or a potential suitor?
Interim data on IPIX new antibiotic tomorrow. Does anyone follow
What are your expectations for Th/FRI? and how do you think the stock price will be effected?
I expect positive results that should move the stock more than 100%. The only thing that concerns me is the lack of run-up prior to this announced news date.
There is a debate on AMRN board re: Secondary outcomes. Can anyone help clarify
NAVB I find it hard to fathom
that Harvard / Ohio State med are involved
with an inconsequential presentation
NAVB can anyone shed some light
on the technical announcements made today
Dew , Have you altered your opinion of AEMD since your last post on this company?
This board is deafeningly silent re: MNKD. Based on the history of many posters, someone must have some insight???
Dew, would your opinion change re: AEMD if the current 10 patient study was positive? Why do you think the government has continued to fund this company?
Has anyone done any research on AEMD. Highly speculative, but concept is inviting. I took a small starter position based on recent news, but could use some help re: validity of the science.
Any thoughts out there?